The board of directors of Xbrane Biopharma has decided to shift strategic focus in the Company’s product pipeline to biosimilars.
As Xbrane’s leading biosimilar Xlucane (ranibizumab (Lucentis) biosimilar) moves into the pivotal clinical trial, Xbrane is accelerating development of Xcimzane (certoizumab pegol (Cimzia) biosimilar) and Xoncane (pegaspargase (Oncaspar) biosimilar) and will initiate development of two additional biosimilars on biologics with patent expiration 2026-2028.
The co-development agreement for Xlucane entered with STADA Arzneimittel AG in July 2018 validated the quality and commercial viability of Xbrane’s technological platform and capability in biosimilar development. This combined with the inherent attractiveness, particularly considering the favourable risk/reward profile, of biosimilars, the board of directors of Xbrane has decided to dedicate the absolute majority of the Company’s development resources to biosimilars going forward.
Xbrane is accelerating the development of Xcimzane (Cimzia biosimilar) and Xoncane (Oncaspar biosimilar. Cimzia is a TNF inhibitor approved for treatment of rheumatoid arthritis, psoriasis and Crohn’s disease with annual sales of €1.4 billion in 2017. The main patents are set to expire in 2024 in Europe and the US. Oncaspar is used in the treatment of acute lymphocytic leukaemia, a disease affecting especially children. The product had annual sales of approx. USD 0.2 billion in 2017.
“As Xlucane moves into the clinical trial we are now able to dedicate more development resources to Xcimzane and Xoncane programs. We are excited about these programs as we see very limited competition and an opportunity to bring the first biosimilars to market. Further, both products are well suited for our patented protein expression technology that will provide us with a cost advantage.” says Martin Åmark, CEO Xbrane.
Leer el artículo original completo